Primmune Therapeutics is a clinical-stage biotechnology company headquartered in Carlsbad, California, developing systemic cancer immunotherapies designed to activate the immune system in a precise and controlled manner. Its lead program, PRTX007, is an orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7) engineered to activate plasmacytoid dendritic cells so they produce interferons, enhance antigen presentation, recruit natural killer cells and support cytotoxic T cell expansion, while minimizing pro-inflammatory signaling. The company was founded by researchers in oral small-molecule drug design and immune agonist pharmacology and has completed Phase 1 evaluation in healthy volunteers. Primmune operates no developer program and publishes no API product, SDK, or interface contract; its public web presence is a WordPress marketing and investor-relations site, whose only machine-readable surfaces are the Yoast-generated /llms.txt and WordPress's default /wp-json/ CMS endpoint.
Primmune Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Clinical Stage, and Immunotherapy.
Primmune Therapeutics’ developer surface includes engineering blog and 5 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/primmune-therapeutics/"><img src="https://apis.io/badge/primmune-therapeutics/card.svg" alt="Primmune Therapeutics on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: primmune-therapeutics
name: Primmune Therapeutics
description: Primmune Therapeutics is a clinical-stage biotechnology company headquartered in Carlsbad, California, developing
systemic cancer immunotherapies designed to activate the immune system in a precise and controlled manner. Its lead program,
PRTX007, is an orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7) engineered
to activate plasmacytoid dendritic cells so they produce interferons, enhance antigen presentation, recruit natural killer
cells and support cytotoxic T cell expansion, while minimizing pro-inflammatory signaling. The company was founded by researchers
in oral small-molecule drug design and immune agonist pharmacology and has completed Phase 1 evaluation in healthy volunteers.
Primmune operates no developer program and publishes no API product, SDK, or interface contract; its public web presence
is a WordPress marketing and investor-relations site, whose only machine-readable surfaces are the Yoast-generated /llms.txt
and WordPress's default /wp-json/ CMS endpoint.
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
image: https://www.primmunerx.com/wp-content/uploads/2017/12/cropped-primmune-favicon-192x192.png
url: https://raw.githubusercontent.com/api-evangelist/primmune-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Clinical Stage
- Immunotherapy
- Oncology
- Life Sciences
- Drug Discovery
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://www.primmunerx.com/
- type: Blog
url: https://www.primmunerx.com/news/
- type: BlogRSS
url: https://www.primmunerx.com/feed/
- type: PrivacyPolicy
url: https://www.primmunerx.com/privacy-policy/
- type: LLMsTxt
url: llms/primmune-therapeutics-llms.txt
- type: DomainSecurity
url: security/primmune-therapeutics-domain-security.yml
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: 'Primmune is a clinical-stage drug developer whose product is the oral TLR7 agonist PRTX007, not software: its single
public host www.primmunerx.com is a WordPress marketing and investor site where /openapi.json, /swagger.json, /api-docs,
/graphql, /mcp and every /.well-known/ path return 404, and the only machine-readable surfaces are a Yoast-generated /llms.txt
listing team and press-release pages and WordPress''s stock /wp-json/ CMS endpoint, which is theme infrastructure rather
than an API the company publishes.'
evidence:
- url: https://www.primmunerx.com/openapi.json
status: 404
- url: https://www.primmunerx.com/graphql
status: 404
- url: https://www.primmunerx.com/.well-known/agent-card.json
status: 404
- url: https://www.primmunerx.com/llms.txt
status: 200
- url: https://www.primmunerx.com/wp-json/
status: 200
checked: '2026-08-26'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.